Advertisement

CD30+ Cutaneous Lymphoproliferative Disorders and Pseudolymphomas

Chapter

Abstract

CD30+ cutaneous lymphoproliferative diseases (CD30CLPD) comprise a spectrum ranging from clinically benign lymphomatoid papulosis (LyP) to primary cutaneous anaplastic large cell lymphomas (ALCL). Between ends of the spectrum are borderline cases not readily assigned to LyP or ALCL. Overall survival and disease-related survival for these disorders are excellent. However, LyP patients have a risk of developing a malignant lymphoma (usually mycosis fungoides, ALCL, or Hodgkin lymphoma). LyP and associated T-cell lymphomas are often clonally related. Fortunately, the risk of LyP patients developing a fatal extracutaneous lymphoma is less than 5 %. LyP patients also are at increased risk of developing a nonlymphoid malignancy. LyP lesions vary greatly in histology according to the age of the lesion. Five different histologic types are described. All but type B feature CD30+ cells. Skin conditions containing CD30+ cells must be distinguished from LyP. LyP resembles pityriasis lichenoides clinically but can be distinguished by combined histopathologic and immunohistochemical features. Primary cutaneous ALCL can be distinguished from secondary skin lesions of systemic ALCL by expression of CLA and lack of EMA and ALK.

Keywords

Anaplastic Lymphoma Kinase Anaplastic Large Cell Lymphoma Mycosis Fungoides Lymphomatoid Papulosis Cutaneous Lymphocyte Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Basarab T, Fraser-Andrews EA, Orchard G, Whittaker S, Russel-Jones R. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol. 1998;139:630–8.PubMedCrossRefGoogle Scholar
  2. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.PubMedGoogle Scholar
  3. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126:596–602.PubMedCrossRefGoogle Scholar
  4. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119:1643–9.PubMedCrossRefGoogle Scholar
  5. Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, et al. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol. 1996;149:483–92.PubMedCentralPubMedGoogle Scholar
  6. Boccara O, Blanche S, de Prost Y, Brousse N, Bodemer C, Fraitag S. Cutaneous hematologic disorders in children. Pediatr Blood Cancer. 2012;58:226–32.PubMedCrossRefGoogle Scholar
  7. Burg G, Kempf W, Kazakov DV, Dummer R, Frosch PJ, Lange-Ionescu S, et al. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol. 2003;148:580–6.PubMedCrossRefGoogle Scholar
  8. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med. 1995;122:210–7.PubMedCrossRefGoogle Scholar
  9. Cappelin D, Idrissi Y, Prochazkova-Carlotti M, Lahranne E, De Sousa Goes AC, et al. Chromosomal rearrangements at 6p25.3 in cutaneous T-cell lymphomas highlight the role of the DUSP22-phosphatase in oncogenesis. In: The International Program Committee and Local Organizing Committee, editors. Proceedings of 2nd world congress of cutaneous lymphomas; 2013; Berlin.Google Scholar
  10. Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin ME. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996;106:696–700.PubMedCrossRefGoogle Scholar
  11. Csikesz CR, Knudson RA, Greipp PT, Feldman AL, Kadin M. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22. J Invest Dermatol. 2013;133:1680–2.PubMedCrossRefGoogle Scholar
  12. Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin ME. Hodgkin’s disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992;326:1115–22.PubMedCrossRefGoogle Scholar
  13. de Bruin PC, Beljaards RC, van Heerde P, Van Der Valk P, Noorduyn LA, Van Krieken JH, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127–35.PubMedCrossRefGoogle Scholar
  14. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–41.PubMedGoogle Scholar
  15. Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV + and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011–4.PubMedCrossRefGoogle Scholar
  16. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. 2004;140:441–7.PubMedGoogle Scholar
  17. el-Azhary RA, Gibson LE, Kurtin PJ, Pittelkow MR, Muller SA. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol. 1994;30:210–8.PubMedCrossRefGoogle Scholar
  18. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23:574–80.PubMedCentralPubMedCrossRefGoogle Scholar
  19. Gellrich S, Wernicke M, Wilks A, Lukowsky A, Muche JM, Jasch KC, et al. The cell infiltrate in lymphomatoid papulosis comprises a mixture of polyclonal large atypical cells (CD30-positive) and smaller monoclonal T cells (CD30-negative). J Invest Dermatol. 2004;122:859–61.PubMedCrossRefGoogle Scholar
  20. Gelmetti C, Rigoni C, Alessi E, Ermacora E, Berti E, Caputo R. Pityriasis lichenoides in children: a long-term follow-up of eighty-nine cases. J Am Acad Dermatol. 1990;23:473–8.PubMedCrossRefGoogle Scholar
  21. Hernandez-Machin B, de Misa RF, Montenegro T, Rivero JC, Bastida J, Febles C, et al. MUM1 expression does not differentiate primary cutaneous anaplastic large-cell lymphoma and lymphomatoid papulosis. Br J Dermatol. 2009;160:713.PubMedCrossRefGoogle Scholar
  22. Humme D, Lukowsky A, Steinhoff M, Beyer M, Walden P, Sterry W, et al. Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol. 2009;129:89–98.PubMedCrossRefGoogle Scholar
  23. Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park). 2009;23:1158–64.Google Scholar
  24. Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin’s disease-associated antigens. Am J Pathol. 1985;119:315–25.PubMedCentralPubMedGoogle Scholar
  25. Kadin ME, Pinkus JL, Pinkus GS, Duran IH, Fuller CE, Onciu M, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008;32:1421–6.PubMedCrossRefGoogle Scholar
  26. Karai LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173–81.PubMedCrossRefGoogle Scholar
  27. Kato N, Tomita Y, Yoshida K, Hisai H. Involvement of the tongue by lymphomatoid papulosis. Am J Dermatopathol. 1998;20:522–6.PubMedCrossRefGoogle Scholar
  28. Kato N, Mizuno O, Ito K, Kimura K, Shibata M. Neutrophil-rich anaplastic large cell lymphoma presenting in the skin. Am J Dermatopathol. 2003;25:142–7.PubMedCrossRefGoogle Scholar
  29. Kempf W, Kazakov DV, Palmedo G, Fraitag S, Schaerer L, Kutzner H. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol. 2012;36:1021–9.PubMedCrossRefGoogle Scholar
  30. Kempf W, Kazakov DV, Scharer L, Rutten A, Mentzel T, Paredes BE, et al. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol. 2013;37:1–13.PubMedCrossRefGoogle Scholar
  31. Kim JE, Yun WJ, Mun SK, Yoon GS, Huh J, Choi JH, et al. Pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica: comparison of lesional T-cell subsets and investigation of viral associations. J Cutan Pathol. 2011;38:649–56.PubMedCrossRefGoogle Scholar
  32. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol. 1997;109:636–40.PubMedCrossRefGoogle Scholar
  33. Lee JS, Park MY, Kim YJ, Kil HI, Choi YH, Kim YC. Histopathological features in both the eschar and erythematous lesions of Tsutsugamushi Disease: identification of CD30+ cell infiltration in Tsutsugamushi disease. The American Journal of dermatopathology 2009;31:551–6.PubMedCrossRefGoogle Scholar
  34. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign–histologically malignant. Arch Dermatol. 1968;97:23–30.PubMedCrossRefGoogle Scholar
  35. Magro CM, Crowson AN, Morrison C, Merati K, Porcu P, Wright ED. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol. 2006;125:490–501.PubMedCrossRefGoogle Scholar
  36. Magro CM, Crowson AN, Morrison C, Li J. Pityriasis lichenoides chronica: stratification by molecular and phenotypic profile. Hum Pathol. 2007;38:479–90.PubMedCrossRefGoogle Scholar
  37. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003;101:1513–9.PubMedCrossRefGoogle Scholar
  38. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140:306–12.PubMedCrossRefGoogle Scholar
  39. Peters K, Knoll JH, Kadin ME. Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis. Cancer Genet Cytogenet. 1995;80:13–6.PubMedCrossRefGoogle Scholar
  40. Plaza JA, Feldman AL, Magro C. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases. J Cutan Pathol. 2013;40:236–47.PubMedCrossRefGoogle Scholar
  41. Polski JM, Janney CG. Ber-H2 (CD30) immunohistochemical staining in malignant melanoma. Mod Pathol. 1999;12:903–6.PubMedGoogle Scholar
  42. Pulitzer MP, Nolan KA, Oshman RG, Phelps RG. CD30+ Lymphomatoid Drug Reactions. Am J Dermatopathol 2013;35:343–50.PubMedCrossRefGoogle Scholar
  43. Ralfkiaer E, Bosq J, Gatter KC, Schwarting R, Gerdes J, Stein H, et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res. 1987;279:285–92.PubMedCrossRefGoogle Scholar
  44. Riboni R, Lucioni M, Araini L, Marta N, Maffie A, Dallera E, et al. High rate of TCR gamma gene rearrangement with clonal identity of microdissected CD30+ cells from lymphomatoid papulosis (LyP). In: The international program committee and Local Organizing Committee, editors. Proceedings of 2nd world congress of cutaneous lymphomas; 2013; Berlin.Google Scholar
  45. Saggini A, Gulia A, Argenyi Z, Fink-Puches R, Lissia A, Magana M, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol. 2010;34:1168–75.PubMedCrossRefGoogle Scholar
  46. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood. 1999;94:2854–61.PubMedGoogle Scholar
  47. Shidham VB, Qi D, Rao RN, Acker SM, Chang CC, Kampalath B, et al. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with ‘MCW melanoma cocktail’–a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer. 2003;3:15.PubMedCentralPubMedCrossRefGoogle Scholar
  48. Steinhoff M, Hummel M, Anagnostopoulos I, Kaudewitz P, Seitz V, Assaf C, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood. 2002;100:578–84.PubMedCrossRefGoogle Scholar
  49. Volkenandt M, Bertino JR, Shenoy BV, Koch OM, Kadin ME. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. J Dermatol Sci. 1993;6:121–6.PubMedCrossRefGoogle Scholar
  50. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer. 1992;70:2951–7.PubMedCrossRefGoogle Scholar
  51. Wang HH, Myers T, Lach LJ, Hsieh CC, Kadin ME. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86:1240–5.PubMedCrossRefGoogle Scholar
  52. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 2005;65:7628–34.PubMedGoogle Scholar
  53. Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008;35:1100–7.PubMedCrossRefGoogle Scholar
  54. Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995;105:51–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Dermatology, Roger Williams Medical CenterBoston University School of MedicineProvidenceUSA

Personalised recommendations